Prophase Labs Inc (PRPH) Stock Analysis
Verdict: AVOID
Extreme liquidity crisis with $90k cash against $53M current liabilities makes insolvency nearly certain without immediate massive dilution.
Investment score: 12/100
Analysis as of
Is Prophase Labs Inc stock worth reviewing? The TradeMates thesis
ProPhase Labs is in a state of financial collapse. Revenue has plummeted from $122M in 2022 to $4.3M in 2025, while the debt load and current liabilities have become insurmountable relative to a $90k cash position. The model sees no path to recovery without total wipeout of current shareholders.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 2/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Prophase Labs Inc opportunities and risks
What speaks for PRPH
- Restructuring or M&A Hail Mary
What speaks against PRPH
- Imminent Bankruptcy Filing
Peers and competitors
- EMMA
- CBGL
- PHBI
- ITNS
- NUGS
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PRPH | n/a | 0.2x | n/a | 30.2% | -709.4% | -4969.2% |
| EMMA | n/a | 0.1x | n/a | 93.3% | -70.6% | -90.5% |
| CBGL | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
| PHBI | n/a | 0.1x | n/a | -0.0% | -29.1% | -2.6% |
| ITNS | n/a | 8200.3x | n/a | 0.0% | -15224.1% | 0.0% |
| NUGS | n/a | 0.0x | n/a | 9.4% | -87.3% | -759.9% |
| Peer median | n/a | 0.1x | n/a | 0.0% | -70.6% | -2.6% |
Frequently asked questions about Prophase Labs Inc (PRPH)
Is PRPH stock a good investment?
The TradeMates model rates Prophase Labs Inc as AVOID with an investment score of 12/100. ProPhase Labs is in a state of financial collapse. Revenue has plummeted from $122M in 2022 to $4.3M in 2025, while the debt load and current liabilities have become insurmountable relative to a $90k cash position. The model sees no path to recovery without total wipeout of current shareholders. This is algorithmic model output, not personal investment advice.
Is PRPH stock a buy?
The TradeMates model verdict for PRPH is AVOID with an investment score of 12/100. Treat this as a model signal to review, not a personal buy recommendation.